Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jochen Utikal

Showing results (241-250 of 276) with videos related to

Pageof 28
Sort By:
European Journal of Cancer (Oxford, England : 1990)|February 12, 2019
Impact of radiation, systemic therapy and treatment sequencing on survival of patients with melanoma brain metastasesRicarda Rauschenberg, Johannes Bruns, Julia Brütting, et al.
European Journal of Cancer (Oxford, England : 1990)|July 17, 2024
Shortened progression free and overall survival to immune-checkpoint inhibitors in BRAF-, RAS- and NF1- ("Triple") wild type melanomasPhilipp Jansen, Wolfgang Galetzka, Georg C Lodde, et al.
European Journal of Cancer (Oxford, England : 1990)|May 28, 2023
Immune checkpoint inhibition in patients with NRAS mutated and NRAS wild type melanoma: a multicenter Dermatologic Cooperative Oncology Group study on 637 patients from the prospective skin cancer registry ADOREGAnne Zaremba, Peter Mohr, Ralf Gutzmer, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 30, 2026
Role of comorbidities and medication on immunotherapy efficacy in cSCC: A DeCOG multicentre analysisGlenn Geidel, Sabrina Bänsch, Laura Adam, et al.
Circulation. Genomic and Precision Medicine|March 17, 2018
Ion Channel Dysfunctions in Dilated Cardiomyopathy in Limb-Girdle Muscular DystrophyIbrahim El-Battrawy, Zhihan Zhao, Huan Lan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 28, 2025
A Phase I, First-in-Human, Dose-Escalation, Expansion Trial of Cytokine-Encoding Synthetic mRNA Mixture Alone or with Cemiplimab in Advanced Solid TumorsOliver Bechter, Carmen Loquai, Stephane Champiat, et al.
Ebiomedicine|September 3, 2023
Correlation of tumor PD-L1 expression in different tissue types and outcome of PD-1-based immunotherapy in metastatic melanoma - analysis of the DeCOG prospective multicenter cohort study ADOREG/TRIMJan-Malte Placke, Mona Kimmig, Klaus Griewank, et al.
The New England Journal of Medicine|June 6, 2012
Improved survival with MEK inhibition in BRAF-mutated melanomaKeith T Flaherty, Caroline Robert, Peter Hersey, et al.
Frontiers in Immunology|June 25, 2024
Optimizing immune checkpoint blockade in metastatic uveal melanoma: exploring the association of overall survival and the occurrence of adverse eventsElias A T Koch, Anne Petzold, Edgar Dippel, et al.
European Journal of Cancer (Oxford, England : 1990)|November 6, 2021
NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitorsCarl M Thielmann, Eleftheria Chorti, Johanna Matull, et al.
Pageof 28

Showing results (241-250 of 276) with videos related to

Sort By:
Pageof 28
European Journal of Cancer (Oxford, England : 1990)|February 12, 2019
Impact of radiation, systemic therapy and treatment sequencing on survival of patients with melanoma brain metastasesRicarda Rauschenberg, Johannes Bruns, Julia Brütting, et al.
European Journal of Cancer (Oxford, England : 1990)|July 17, 2024
Shortened progression free and overall survival to immune-checkpoint inhibitors in BRAF-, RAS- and NF1- ("Triple") wild type melanomasPhilipp Jansen, Wolfgang Galetzka, Georg C Lodde, et al.
European Journal of Cancer (Oxford, England : 1990)|May 28, 2023
Immune checkpoint inhibition in patients with NRAS mutated and NRAS wild type melanoma: a multicenter Dermatologic Cooperative Oncology Group study on 637 patients from the prospective skin cancer registry ADOREGAnne Zaremba, Peter Mohr, Ralf Gutzmer, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 30, 2026
Role of comorbidities and medication on immunotherapy efficacy in cSCC: A DeCOG multicentre analysisGlenn Geidel, Sabrina Bänsch, Laura Adam, et al.
Circulation. Genomic and Precision Medicine|March 17, 2018
Ion Channel Dysfunctions in Dilated Cardiomyopathy in Limb-Girdle Muscular DystrophyIbrahim El-Battrawy, Zhihan Zhao, Huan Lan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 28, 2025
A Phase I, First-in-Human, Dose-Escalation, Expansion Trial of Cytokine-Encoding Synthetic mRNA Mixture Alone or with Cemiplimab in Advanced Solid TumorsOliver Bechter, Carmen Loquai, Stephane Champiat, et al.
Ebiomedicine|September 3, 2023
Correlation of tumor PD-L1 expression in different tissue types and outcome of PD-1-based immunotherapy in metastatic melanoma - analysis of the DeCOG prospective multicenter cohort study ADOREG/TRIMJan-Malte Placke, Mona Kimmig, Klaus Griewank, et al.
The New England Journal of Medicine|June 6, 2012
Improved survival with MEK inhibition in BRAF-mutated melanomaKeith T Flaherty, Caroline Robert, Peter Hersey, et al.
Frontiers in Immunology|June 25, 2024
Optimizing immune checkpoint blockade in metastatic uveal melanoma: exploring the association of overall survival and the occurrence of adverse eventsElias A T Koch, Anne Petzold, Edgar Dippel, et al.
European Journal of Cancer (Oxford, England : 1990)|November 6, 2021
NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitorsCarl M Thielmann, Eleftheria Chorti, Johanna Matull, et al.
Pageof 28